T he purpose of this program and research award is to stimulate physicians-in-training to pursue a career in clinical research in hypertension. The research fellow must be conducting work in which he is the major senior investigator in any area of his choice including clinical or laboratory aspects of the hypertensive diseases. The fellow's work would be supervised by the director of the research training program (the mentor), but the conduct of the investigation is primarily by the research fellow. The winning presentation receives $3,000 and the fellow's mentor receives $25,000 to support the clinical investigative training of a research fellow the following year.
In his illustrious career, Dr Streeten was one of the first clinical investigators to explore the endocrine aspects of hypertension and hypotension by evaluating the role of vasoconstricting and vasodilating factors. He's also noted for training a generation of young physicians in the rigors and discipline of clinical research.
Meanwhile, he has played a pivotal role in various professional organizations, including president of the Syracuse Chapter of the American Diabetes Association and charter member of the American Society of Hypertension and American Autonomic Society. With the American Heart Association, Dr Streeten is a fellow of the National Council for High Blood Pressure Research. He also served on the AHA New York Affiliate's Hypertension Committee.
For these-and many other reasons during his distinguished career-the Council for High Blood Pressure Research honors David H.P. Streeten as the Second Irvine Page-Alva Bradley Lifetime Achievement Award recipient. Masashi Yanagisawa, MD, PhD for his discovery of endothelin and its role for hypertension in vascular biology.
Past Recipients of the Lifetime Achievement Award
Dr Masashi Yanagisawa received the Novartis Award in Hypertension Research for his discovery of endothelin and his studies of its role in hypertension and vascular biology. He received his MD and PhD from the University of Tsukuba in Japan and joined the faculty of Kyoto University in 1991 as an Assistant Professor of Medicine. He later moved to the University of Texas Southwestern Medical School in Dallas as an Associate Professor of Molecular Genetics. He is currently a Professor of Molecular Genetics and a Howard Hughes Investigator at the institution and holds the George L. MacGregor Distinguished Chair in Biomedical Science. He has published over 130 articles in major scientific journals. His discovery of the endothelins marked a milestone in cardiovascular research and has stimulated academic and industrial research worldwide. Building on the observation that endothelial cells release a vasoconstrictor peptide, Dr Yanagisawa and colleagues isolated, purified and determined the amino acid sequence the active peptide, endothelin-1. Additionally, they cloned and expressed the preproendothelin peptide and determined its enzymatic processing to endothelin-1, endothelin-2 and endothelin-3. The peptide was shown to be a potent and long acting vasoconstrictor in isolated vascular tissue and intact rats. This complete description of endothelin biology was published as a single article in Nature in 1988 and by 1992 became the second most cited paper in biological sciences. In subsequent studies, he purified and cloned the two receptors for endothelins and two endothelin converting enzymes. Using gene knockout techniques to eliminate the endothelin peptides, endothelin receptors and endothelin converting enzymes, he has determined the role of the endothelins in cardiovascular control and development. These knockout experiments established the prohypertensive role for endogenous endothelins. These studies were followed by a description of mutations in the human gene for the endothelin B receptor that results in Hirschprung's disease. Portions of this research was presented as a Arthur C. Corcoran Memorial Lecture to the Council for High Blood Pressure Research in 1995. The pharmacological and therapeutic implications of his discoveries are now being realized. Drugs that inhibit the endothelin receptors and endothelin converting enzyme have been developed and are entering clinical trials. These drugs show promise in treating hypertension, congestive heart failure and vasospasm.
His laboratory continues the investigation on the physiological and pathophysiological roles of endothelins using genetically modified rodent strains, addressing fundamental questions in blood pressure regulation and other cardiovascular functions. In addition, in 1998, his group discovered orexins, novel hypothalamic neuropeptides that regulate feeding behavior, as endogenous ligands for "orphan" G protein-coupled receptors.
Harry Goldblatt Award 1998
T he Goldblatt Award is presented each year to the author(s) of the paper(s) from last year's meeting judged by the Publication Committee of the Council for High Blood Pressure Research to represent the most significant new contribution to the understanding of the causes and/or consequences of hypertension. The award is named for the eminent hypertension researcher Dr Harry Goldblatt and is supported by a generous donation to the council from his family. Included with the award is a $1,000 honorarium and a commemorative plaque.
The 1998 Goldblatt Award was presented to Dr Edward W. Inscho from the Department of Physiology, Tulane University School of Medicine. Dr Inscho is a fellow of the Council for High Blood Pressure Research and has been a member of the council for many years. Dr Inscho's research interests have concentrated on the study of renal microvascular control systems with principal emphasis on renal purinoceptors. His earlier interests focused on understanding the role of extracellular ATP and P 2 receptors in the regulation of renal microvascular function. Those studies revealed that ATP activates L-type calcium channels, potently vasoconstricts the preglomerular microvasculature and that P 2 receptor activation may be responsible for mediating autoregulatory adjustments in renal vascular resistance. This led to a more basic interest in questions related to the intracellular signaling mechanisms utilized by renal microvascular smooth muscle in responding to physiological stimuli. To pursue such issues, Dr Inscho and colleagues began to investigate the calcium signaling pathways utilized by renal microvascular smooth muscle in responding to vasoactive agonists as well as to changes in renal perfusion pressure. In particular, they have been interested in the relative roles of calcium influx and of calcium release from intracellular stores in the response of afferent and efferent arterioles to renal vasoconstrictors. These studies are being performed using intact pre-and postglomerular arterioles and freshly isolated preglomerular smooth muscle cells. To date, he has determined that calcium mobilization from intracellular stores represents an essential component in the pre-and postglomerular response to vasoconstrictor agonists. Furthermore, those studies have shown that postglomerular efferent arterioles may be more reliant on the release of stored calcium than afferent arterioles in response to the same agonist and suggests the activation of different calcium signaling cascades by these two glomerular resistance elements.
The work presented for the Goldblatt Award represents Dr Inscho's beginning investigations into the role of intracellular calcium stores in preglomerular autoregulatory responses. The paper entitled "Calcium Mobilization Contributes to PressureMediated Afferent Arteriolar Vasoconstriction" revealed that pressure-induced autoregulatory adjustments in afferent arteriolar diameter involved the release of stored calcium. Experimental manipulations designed to deplete intracellular calcium pools while retaining normal extracellular calcium concentrations resulted in marked attenuation of pressure-dependent vasoconstriction of afferent arterioles. Furthermore, these studies demonstrated that activation of phospholipase C is an important component of pressure-mediated afferent arteriolar vasoconstrictor responses and implicated inositoltrisphosphate-generation in the pressureinduced calcium signaling cascade. The significance of this work stems from our growing recognition that pre-and postglomerular signal transduction mechanisms may have evolved separately to fulfill specific physiological functions. Thus, only by investigating these mechanisms at the microvascular level can we begin to appreciate and understand the unique nature of the local renal microvascular regulation. Dr Oparil held a faculty position at the University of Chicago Presbyterian School of Medicine prior to moving to the University of Alabama at Birmingham, where she worked with Drs Harriet Dustan and Thomas James, both past presidents of the American Heart Association, to develop an interdepartmental research program focused on hypertension and vascular biology. She directs a postdoctoral research program which has trained numerous investigators who now hold major academic positions in universities throughout the world. Dr Oparil's laboratory is currently focused on studies of the effects of ovarian hormones, both estrogens and progestins, on blood vessels and on vascular responses to injury. Her fundamental studies have the long-term goal of elucidating the mechanisms by which loss of ovarian function promotes the development of atherosclerotic disease and heart attack in women. The results of these studies have already provided important new insights into novel treatments and preventive strategies for vascular disease, including gene therapy. The highlights of these findings were the subject of the 1998 Arthur C. Corcoran Memorial Lecture.
In addition to her scientific contribution, Dr Oparil has been active in a leadership and policy making role in a number of professional and voluntary health organizations. She served as President of the American Federation of Clinical (now Medical) Research, the largest (13,000 members) clinical research organization in the world. She had previously served as Chairman of the Public Policy Committee of that organization, where she formulated science policy positions that affect biomedical research at the national level. Dr Oparil is also a member of the American Society of Clinical Investigation, having served as its Secretary-Treasurer for 3 years, of the Association of American Physicians, and of the prestigious institute of Medicine (IOM) of the National Academy of Sciences.
Dr Oparil is an active volunteer in the American Heart Association at both the national and affiliate levels. She is a Past President of that organization. Dr Oparil has also held important advisory positions with the National Institutes of Health (NIH), including membership on a number of task forces, advisory committees and peer review committees. T he purpose of the Merck New Investigator Award is to encourage young investigators to undertake or continue hypertension research and participate in the conference. The award permits a young investigator to travel to the annual meeting and to present research orally or in poster format and to engage in discussion with senior investigators. The candidates are young investigators (MD or PhD), fellows in training, and academicians who hold an academic rank no higher than that of instructor at the time of submission of an abstract. Each awardee (up to 10) receives $1,000.
The Merck New Investigator Award/Latin America is presented with the same criteria to up to five qualified new investigators who plan to pursue their careers in Latin America. Each awardee receives $2,000. 
